HC Wainwright Cuts LENZ Therapeutics Earnings Estimate

Summary

HC Wainwright has revised its earnings expectations for LENZ Therapeutics for Q2 2025, lowering it from $0.60 per share to $0.63 per share. Despite this revision, the company maintains a ‘buy’ rating with a target price of $38.00. The consensus expectation for annual earnings is $2.18 per share. Other analysts have set higher target prices, with an average of $46.60. LENZ’s stock is currently trading at $26.34, with a market capitalization of $741.37 million.Market Beat

Impact Analysis

The event is at the company level, as it directly pertains to LENZ Therapeutics’ financial outlook and stock valuation. The downward revision of earnings expectations suggests potential challenges or adjustments in the company’s operations or market conditions. Despite this, maintaining a ‘buy’ rating indicates confidence in LENZ’s long-term prospects. First-order effects include possible short-term pressure on the stock price due to lowered earnings expectations, while second-order effects could involve broader investor sentiment shifts if other firms in the industry face similar adjustments. Investment opportunities may arise if LENZ’s stock is perceived as undervalued given the target price discrepancy among analysts, suggesting potential upside if the company meets or exceeds revised forecasts.Market Beat